Last reviewed 2026-04-20 · How we verify

Placebp (placebp)

Placebp is a placebo marketed by Pfizer, primarily indicated for use in clinical trials for Major Depressive Disorder. Its key strength lies in serving as a reliable control in clinical trials, essential for establishing the efficacy of new treatments. The primary risk is the availability of established alternatives such as Sertraline and Lithium, which may limit the demand for placebo-controlled trials.

At a glance

Approved indications

• Major Depressive Disorder

Common side effects

No common side effects on file.

Drug interactions

• Alprazolam
• Cimetidine
• Ciprofloxacin
• Diltiazem
• Erythromycin
• Fluoxetine
• Itraconazole
• Ketoconazole
• Omeprazole
• Rifampin
• Ritonavir
• Verapamil

Key clinical trials

• A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants (PHASE3)
• Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients (PHASE2)
• Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis (PHASE2)
• Safety and Efficacy of Oral Bovine Lactoferrin (EARLY_PHASE1)
• Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Placebp CI brief — competitive landscape report
• Placebp updates RSS · CI watch RSS
• Pfizer portfolio CI